NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Long-term Follow-up (LTFU) of Patients Treated With Genome-edited Autologous Hematopoietic Stem and Progenitor Cells (HSPC)

NCT06155500

Active Not RecruitingPhase 1

Sponsor: Novartis Pharmaceuticals

Conditions: Sickle Cell Disease

Interventions: OTQ923

Countries: United States

CADPT03A12001 is a prospective, multi-center study that is designed to follow all enrolled patients who have received treatment with OTQ923 for long-term safety and efficacy.

Eligibility overview

Sex: ALL

Age: 18 Years to 100 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Patients must have received gene therapy treatment from the parent treatment protocol (CADPT03A12101).
2. Patients must provide informed consent prior to their entry into this study.

Exclusion Criteria:

1\. Completion of less than 1 year of safety follow-up in the treatment protocol (CADPT03A12101).

Locations (3)

Chicago, Illinois, United States
New York, New York, United States
Memphis, Tennessee, United States